Is the incidence and prevalence of inhibitors greater with recombinant products? Yes

被引:31
作者
Aledort, LM [1 ]
机构
[1] CUNY Mt Sinai Sch Med, New York, NY 10029 USA
关键词
D O I
10.1111/j.1538-7836.2004.00731.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In summary, it is unlikely that in the near future we will have sufficient prospective randomized studies to resolve definitively the dilemma of inhibitor induction. Therefore, both physicians and patients need to recognize that choosing a recombinant therapeutic product may well increase the risk of this major complication of therapy. © 2004 International Society on Thrombosis and Haemostasis.
引用
收藏
页码:861 / 862
页数:2
相关论文
共 11 条
[1]   INHIBITORS IN HEMOPHILIA PATIENTS - CURRENT STATUS AND MANAGEMENT [J].
ALEDORT, L .
AMERICAN JOURNAL OF HEMATOLOGY, 1994, 47 (03) :208-217
[2]  
BRAY GL, 1994, BLOOD, V83, P2428
[3]   INCIDENCE OF DEVELOPMENT OF FACTOR-VIII AND FACTOR-IX INHIBITORS IN HEMOPHILIACS [J].
EHRENFORTH, S ;
KREUZ, W ;
SCHARRER, I ;
LINDE, R ;
FUNK, M ;
GUNGOR, T ;
KRACKHARDT, B ;
KORNHUBER, B .
LANCET, 1992, 339 (8793) :594-598
[4]   RECOMBINANT FACTOR-VIII FOR THE TREATMENT OF PREVIOUSLY UNTREATED PATIENTS WITH HEMOPHILIA-A - SAFETY, EFFICACY, AND DEVELOPMENT OF INHIBITORS [J].
LUSHER, JM ;
ARKIN, S ;
ABILDGAARD, CF ;
SCHWARTZ, RS .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (07) :453-459
[5]  
NILSSON IM, 1993, RECENT DEV STUDY INH, P15
[6]  
PEERLINCK K, 1993, BLOOD, V81, P3332
[7]   HEMOPHILIACS WITH FACTOR-VIII INHIBITORS IN FINLAND - PREVALENCE, INCIDENCE AND OUTCOME [J].
RASI, V ;
IKKALA, E .
BRITISH JOURNAL OF HAEMATOLOGY, 1990, 76 (03) :369-371
[8]  
ROSENDAAL FR, 1993, BLOOD, V81, P2180
[9]  
ROTHSCHILD C, 2003, J THROMB HAEMOST S, V1
[10]   INCIDENCE OF INHIBITORS IN PATIENTS WITH SEVERE AND MODERATE HEMOPHILIA-A TREATED WITH FACTOR-VIII CONCENTRATES [J].
SCHWARZINGER, I ;
PABINGER, I ;
KORNINGER, C ;
HASCHKE, F ;
KUNDI, M ;
NIESSNER, H ;
LECHNER, K .
AMERICAN JOURNAL OF HEMATOLOGY, 1987, 24 (03) :241-245